Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon beta-1a for mild to moderate outpatient COVID-19
IRCT20120703010178N25Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Aug 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of interferon beta-1a in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Body temperature, Systolic blood pressure and 4 more. Started Aug 2021; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20120703010178N25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120703010178N25.